To address this issue, Eisai is currently conducting phase III studies with lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer (DTC) as part of a global development program that encompasses the US, Europe, Japan and other parts of Asia, with the aim of submitting marketing authorization applications for the agent before the end of fiscal 2013.